Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
The efficacy and safety of zepatier treatment experience in hcv genotype 1 patients
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Department of pharmacy)
- Co-author(s): Tzu-Cheng Tsai
BackgroundZepatier (elbasvir and grazoprevir) is a directly acting antivirals (DAA) for treatment of chronic HCV genotype (GT) 1 or 4 infection in adults. It was approved by TFDA since Dec. 2016, then reimbursement for fibrosis 3 or 4 (F3 or 4) by NHI since Aug. 2017. Approximately 53% of HCV infected patients were genotype 1 in Taiwan, DAA was.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019